Trombòlisi intravenosa en l'ictus isquèmic: evolució 2005-2012

Trombòlisi intravenosa; Ictus; TractamentTrombolisis intravenosa; TratamientoIntravenous thrombolysis; TreatmentL'objectiu de l'atles és identificar i descriure la variabilitat de la trombòlisi intravenosa en l'ictus isquèmic ja que la trombòlisi intravenosa és l'única teràpia que disposa d'evidència científica en el tractament del pacient amb ictus isquèmic en fase aguda

Access to and delivery of acute ischaemic stroke treatments: A survey of national scientific societies and stroke experts in 44 European countries

Acute stroke treatment; Health care resources; Intravenous thrombolysisTractament de l'ictus agut; Recursos sanitaris; Trombòlisi intravenosaTratamiento del ictus agudo; Recursos sanitarios; Trombólisis intravenosaINTRODUCTION: Acute stroke unit care, intravenous thrombolysis and endovascular treatment significantly improve the outcome for patients with ischaemic stroke, but data on access and delivery throughout Europe are lacking. We assessed best available data on access and delivery of acute stroke unit care, intravenous thrombolysis and endovascular treatment throughout Europe. METHODS: A survey, drafted by stroke professionals (ESO, ESMINT, EAN) and a patient organisation (SAFE), was sent to national stroke societies and experts in 51 European countries (World Health Organization definition) requesting experts to provide national data on stroke unit, intravenous thrombolysis and endovascular treatment rates. We compared both pooled and individual national data per one million inhabitants and per 1000 annual incident ischaemic strokes with highest country rates. Population estimates were based on United Nations data, stroke incidences on the Global Burden of Disease Report. RESULTS: We obtained data from 44 European countries. The estimated mean number of stroke units was 2.9 per million inhabitants (95% CI 2.3-3.6) and 1.5 per 1000 annual incident strokes (95% CI 1.1-1.9), highest country rates were 9.2 and 5.8. Intravenous thrombolysis was provided in 42/44 countries. The estimated mean annual number of intravenous thrombolysis was 142.0 per million inhabitants (95% CI 107.4-176.7) and 72.7 per 1000 annual incident strokes (95% CI 54.2-91.2), highest country rates were 412.2 and 205.5. Endovascular treatment was provided in 40/44 countries. The estimated mean annual number of endovascular treatments was 37.1 per million inhabitants (95% CI 26.7-47.5) and 19.3 per 1000 annual incident strokes (95% CI 13.5-25.1), highest country rates were 111.5 and 55.9. Overall, 7.3% of incident ischaemic stroke patients received intravenous thrombolysis (95% CI 5.4-9.1) and 1.9% received endovascular treatment (95% CI 1.3-2.5), highest country rates were 20.6% and 5.6%. CONCLUSION: We observed major inequalities in acute stroke treatment between and within 44 European countries. Our data will assist decision makers implementing tailored stroke care programmes for reducing stroke-related morbidity and mortality in Europe

Segon audit clínic de l’ictus: Catalunya 2008

Audit clínic; Ictus; AvaluacióAudit clínico; Ictus; EvaluaciónClinical audit; Stroke; EvaluationEl document que esteu llegint presenta els resultats del Segon Audit de l’Ictus, realitzat entre febrer i juny del 2008, la part clínica del qual es basa en la revisió d’històries clíniques de pacients amb ictus ingressats consecutivament a partir del gener del 2007 en els 48 hospitals de l’XHUP. La part estructural d’aquest audit descriu la situació dels equipaments, recursos humans i organitzatius per a l’atenció al malalt amb ictus al 2008.Aquest Segon Audit de l’ictus ha estat cofinançat per la Direcció General de Planificació i Avaluació i pel projecte de recerca 05/2709 del Fondo de Investigación Sanitaria, Instituto de Salud Carlos III

Primer audit clínic de l’ictus: Catalunya 2006

Audit clínic; Ictus; AvaluacióAudit clínico; Ictus; EvaluaciónClinical audit; Stroke; EvaluationAquest document presenta els resultats de l’audit clínic i descriu els recursos per a l’atenció a l’ictus a nivell de Catalunya, analitzant la situació dels diferents territoris i nivells hospitalaris.Aquest ’Primer Audit Clínic de l’Ictus’ ha estat finançat amb el projecte de recerca 05/2709 del ‘Fondo de Investigación Sanitaria’

Trombòlisi intravenosa en l'ictus isquèmic: evolució 2005-2012

Trombòlisi intravenosa; Ictus; TractamentTrombolisis intravenosa; TratamientoIntravenous thrombolysis; TreatmentL'objectiu de l'atles és identificar i descriure la variabilitat de la trombòlisi intravenosa en l'ictus isquèmic ja que la trombòlisi intravenosa és l'única teràpia que disposa d'evidència científica en el tractament del pacient amb ictus isquèmic en fase aguda

Access to and delivery of acute ischaemic stroke treatments: A survey of national scientific societies and stroke experts in 44 European countries

Acute stroke treatment; Health care resources; Intravenous thrombolysisTractament de l'ictus agut; Recursos sanitaris; Trombòlisi intravenosaTratamiento del ictus agudo; Recursos sanitarios; Trombólisis intravenosaINTRODUCTION: Acute stroke unit care, intravenous thrombolysis and endovascular treatment significantly improve the outcome for patients with ischaemic stroke, but data on access and delivery throughout Europe are lacking. We assessed best available data on access and delivery of acute stroke unit care, intravenous thrombolysis and endovascular treatment throughout Europe. METHODS: A survey, drafted by stroke professionals (ESO, ESMINT, EAN) and a patient organisation (SAFE), was sent to national stroke societies and experts in 51 European countries (World Health Organization definition) requesting experts to provide national data on stroke unit, intravenous thrombolysis and endovascular treatment rates. We compared both pooled and individual national data per one million inhabitants and per 1000 annual incident ischaemic strokes with highest country rates. Population estimates were based on United Nations data, stroke incidences on the Global Burden of Disease Report. RESULTS: We obtained data from 44 European countries. The estimated mean number of stroke units was 2.9 per million inhabitants (95% CI 2.3-3.6) and 1.5 per 1000 annual incident strokes (95% CI 1.1-1.9), highest country rates were 9.2 and 5.8. Intravenous thrombolysis was provided in 42/44 countries. The estimated mean annual number of intravenous thrombolysis was 142.0 per million inhabitants (95% CI 107.4-176.7) and 72.7 per 1000 annual incident strokes (95% CI 54.2-91.2), highest country rates were 412.2 and 205.5. Endovascular treatment was provided in 40/44 countries. The estimated mean annual number of endovascular treatments was 37.1 per million inhabitants (95% CI 26.7-47.5) and 19.3 per 1000 annual incident strokes (95% CI 13.5-25.1), highest country rates were 111.5 and 55.9. Overall, 7.3% of incident ischaemic stroke patients received intravenous thrombolysis (95% CI 5.4-9.1) and 1.9% received endovascular treatment (95% CI 1.3-2.5), highest country rates were 20.6% and 5.6%. CONCLUSION: We observed major inequalities in acute stroke treatment between and within 44 European countries. Our data will assist decision makers implementing tailored stroke care programmes for reducing stroke-related morbidity and mortality in Europe